Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement

NCT ID: NCT00446693

Last Updated: 2009-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to clinically assess the safety and performance of the EndoFast Reliant™ system as a less invasive treatment for Pelvic Organ Prolapse.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

Pelvic Organ Prolapse represents a significant problem worldwide and may have a significant negative impact on a woman's quality of life. The uterus, rectum and the bladder are held in their normal positions just above the inner end of the vagina by a "hammock" made up of supportive muscles and ligaments. Wear and tear on these supportive structures in the pelvis can allow the uterus, the bladder, the bowels, the vaginal vault or the rectum to sag through the muscle and ligament layers. When this occurs, the rectum, uterus, bowels or bladder can create a bulge into the vagina. In severe cases, it is possible for the sagging rectum, uterus, bowels or bladder to work its way down far enough that the bulge can appear at the vagina's opening or even protrude from the opening. Pelvic Organ Prolapse causes significant discomfort to the patients being associated with urinary incontinence, voiding difficulty culminating with urinary retention, constipation, pain during sexual intercourse, local discomfort, etc.

Treatment Options When symptoms occur, many patients initially opt for conservative treatment. Pelvic exercises and vaginal support are the current mainstays of non surgical management. In addition, patients who are poor surgical candidates or are strongly disinclined to surgery can be offered vaginal support (pessaries) for symptom relief. Topical estrogen is an important adjunct in the conservative management of patients with Pelvic Organ Prolapse. However, the primary management strategy for severe Pelvic Organ Prolapse is surgical. The exact treatment choice will depend on the severity of the prolapse and whether there are any related pelvic floor defects.

Endogun Medical Systems Ltd. has developed an innovative, minimally-invasive system for repair of Pelvic Floor Prolapse. The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with a proprietary system comprised of a mesh and soft tissue fasteners in a minimally-invasive way. The fasteners can be deployed easily and swiftly in narrow spaces into soft tissue and can support substantially more weight than needed for Pelvic Organ Prolapse repair. Following many pre-clinical tests, the EndoFast Reliant™ system is now available for clinical evaluation.

The objective of this study is to evaluate the safety and performance of the EndoFast Reliant™ system for treatment of Pelvic Organ Prolapse.

In particular:

* The study's primary goal is to clinically assess the safety of the EndoFast Reliant™ as a minimally-invasive procedure for vaginal wall reinforcement.
* The study's secondary goal is to clinically evaluate the performance of the EndoFast Reliant™ system as a minimally-invasive procedure for vaginal wall reinforcement by evaluating the improvement in Pelvic Organ Prolapse using the POPQ grading system.

Study Procedures and Follow up:

Pre-treatment tests and inspection will be performed within 4 months prior to surgery.

Approximately two weeks, three months and six months after the surgery the patient will be invited for physician examination and laboratory tests.

Additional Study Measures:

In addition to the endpoint parameters, the following study measures will be collected:

* Symptoms relief and Quality of Life (QOL) considerations.
* Sexual Function considerations, as documented using the Female Sexual Function (FSFI) questionnaire;
* Assessment of the physician's satisfaction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pelvic Organ Prolapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I

Use of EndoFast Reliant System

Group Type EXPERIMENTAL

EndoFast Reliant™ system for Pelvic Organ Prolapse repair

Intervention Type DEVICE

The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EndoFast Reliant™ system for Pelvic Organ Prolapse repair

The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female aged between 40-80 years (inclusive) who is not pregnant or planning to have further births.
* Subject suffers from Pelvic Organ Prolapse confirmed by vaginal inspection.
* Patient under reliable form of contraceptive measure or menopausal.
* Subject able to comprehend procedure and has signed Informed Consent Form for participation in this study.
* Subject able to complete the applicable questionnaires.

Exclusion Criteria

* Planned to undergo hysterectomy.
* Uterine prolapse equal to or greater than 3rd degree.
* Documented Stress Urinary Incontinence on physical examination with full bladder or during complete urodynamic assessment with and without prolapse reduction.
* Any chronic active and uncontrolled disease.
* Vaginal bleeding disorders.
* Needing emergency surgery.
* Any acute disease.
* Blood clotting disorders and/or anticoagulant treatment.
* Known cognitive or psychiatric disorder.
* High operative risk.
* Any ongoing malignant disease.
* Concurrent participation in any other clinical trial
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Endogun Medical Systems Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Endogun Medical Systems Ltd.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Von Theobald, Prof.

Role: PRINCIPAL_INVESTIGATOR

Professeur d'Université-Praticien Hospitalier, gynécologie

Michel Cosson, Prof.

Role: PRINCIPAL_INVESTIGATOR

Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique

Genadi Bitman, MD

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Caen

Caen, , France

Site Status

Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique

Lille, , France

Site Status

Sheba Medical Center

Ramat Gan, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EFPS01

Identifier Type: -

Identifier Source: org_study_id